Martins Eduardo Bruno 4

4 · Sagimet Biosciences Inc. · Filed Jul 20, 2023

Form 4

Period: 2023-07-18

Chief Medical Officer

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−44,009→ 0 total
Exercise: $13.51Exp: 2033-04-19→ Common Stock (44,009 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−198,132→ 0 total
Exercise: $6.36Exp: 2031-02-18→ Common Stock (198,132 underlying)
Award
Stock Option (Right to Buy)
2023-07-18+198,132→ 198,132 total
Exercise: $6.36Exp: 2031-02-18→ Series A Common Stock (198,132 underlying)
Award
Stock Option (Right to Buy)
2023-07-18+44,009→ 44,009 total
Exercise: $13.51Exp: 2033-04-19→ Series A Common Stock (44,009 underlying)

Footnotes (3)

[F1]Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
[F2]25% of the shares underlying this option vested and became exercisable on February 16, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
[F3]The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 20, 2023, subject to the Reporting Person's continued service on each such vesting date.

Documents

1 file